EXOMIND (BTL-699-2) for the Improvement in Willpower & Food Cravings

Completed · Not applicable · Has a placebo group

Conditions studied: Self-Control, Food Cravings

In brief

The goal of this clinical trial is to evaluate if the treatment with ExoMIND (BTL-699-2) device is able to improve willpower, self-control and food cravings in adults above the age of 22 years. The main question it aims to answer is: Does the treatment with EXOMIND (BTL-699-2) device improve willpower, self-control and food cravings? Participants will be asked to: * Undergo six treatments * Complete the Brief Self-control Scale * Complete the Food Cravings Questionnaire - Trait * Complete the Therapy Comfort Questionnaire * Complete the Subject Satisfaction Questionnaire

Key facts

Study ID: NCT07056036
Run by: BTL Industries Ltd.
People needed: 51
Starts: 2024-11-01
Expected to finish: 2025-10-10
Last updated by the study team: 2025-12-10

Who can join

Age: 22 and older. Sex: any. Healthy volunteers: accepted.

You may qualify if…

Age > 22 years
Ability to determine the motor threshold of the participant. The participant's motor threshold could be established as the minimum stimulus required to induce contraction of the right thumb
Subjects willing and able to abstain from partaking in any treatments other than the study procedure for the improvement of willpower and self-control and rI eduction of food cravings, including non-invasive brain stimulation treatments other than the study procedure during study participation
Subjects willing and able to maintain their regular (pre-procedure) exercise regimen without affecting significant change in either direction during study participation
Willingness to comply with study instructions and to return to the clinic for the required visits
Women of child-bearing potential* are required to use birth control measures during the whole duration of the study
If applicable, subjects will be maintained on pre-study prescribed medications at a stable therapeutic dosage for at least 2 months prior to study entry

You may not qualify if…

Electronic implants (Implanted stimulator devices in or near the head - rTMS devices are contraindicated for use in patients who have active or inactive implants (including device leads), deep brain stimulators, cochlear implants, ocular implant, and vagus nerve stimulators, implanted devices such as cardiac pacemakers, defibrillators, neurostimulators. Contraindicated use could result in serious injury or death.
Metallic, conductive, ferromagnetic or other magnetic sensitive implants/objects in the head or within 30 cm of the treatment coil (examples include implanted electrodes/stimulators, aneurysm clips or coils, stents, bullet fragments, jewelry and hair barrettes) with some exceptions in the mouth as standard amalgam dental fillings, single post dental implants, and dental bridge work. Failure to follow this restriction could result in serious injury or death.
Drug pump(s)
Application in the heart area
Persons with a tendency to seizure (hypotonic, epileptic), or a personal history of epilepsy
Ongoing anticoagulation therapy
Ongoing severe or life-threatening condition
Pulmonary insufficiency
Heart disorders
Renal insufficiency
Decompensated* hemorrhagic conditions, blood coagulation disorders, cardiovascular diseases
Malignant or benign tumor
Fever
Ongoing pregnancy or nursing
Ongoing intake disorders such as bulimia or anorexia
Diagnosis of major depression, depression, post-traumatic stress disorder, psychotic disorder or current psychotic symptoms, bipolar disorder, obsessive-compulsive disorder, borderline personality disorder
Personal history of syncope (except the reflex syncope)
Vascular, traumatic, tumoral, infectious, or metabolic lesion of the brain, even without a history of seizure, and without anticonvulsant medication
Withdrawal from one of the following drugs could form a relative hazard for the application of rTMS due to the resulting significant seizure threshold lowering potential: (e.g. alcohol, barbiturates, benzodiazepines, meprobamate, chloralhydrate etc.)
Systemic infection
Patients with a broad range of neuropsychiatric diseases are at elevated risk for seizures. Essentially all neurologic conditions with structural cerebral damage (e.g. stroke, multiple sclerosis, traumatic brain injury, Alzheimer's and other neurodegenerative diseases, meningoencephalitis or intracerebral abscess, parenchymal or leptomeningeal cancers)
History of hyponatremia, hypocalcemia, hypomagnesemia, hypoglycemia, hyperglycemia, renal failure/uremia, liver failure
History of tendency for raised blood concentrations of pro-convulsant medications due to reduced clearance
Immunosuppressive therapy with cyclosporine, tacrolimus and other agents that can cause the posterior reversible leukoencephalopathy syndrome
The use of methamphetamine, barbiturates, cocaine metabolites, opiates and phencyclidine 72 hours before the therapy

Where it is running

A New You Wellness — Miami, Florida, United States
Cady Wellness Institute — Newburgh, Indiana, United States
Jiva Med Spa — Columbus, Ohio, United States
Aria Integrative Health — Denver, Colorado, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.